Sirius Therapeutics Announces First-in-Human Dosing of Its Proprietary siRNA Anticoagulant SRSD107
Sirius Therapeutics
Oligonucleotide Drug Developer
Source:Sirius Therapeutics
Recently, Sirius Therapeutics (SHANGHAI) Co., Ltd. ("Sirius Therapeutics"), announced that the first subject has been successfully dosed on January 30, 2024, in its independently developed next-generation anticoagulant drug SRSD107. SRSD107 is a novel siRNA therapy for the prevention or treatment of thromboembolic diseases and is one of the key product pipelines in the company’s cardiovascular disease portfolio. This Phase 1 clinical study primarily evaluates the tolerability, pharmacokinetics, and pharmacodynamics of SRSD107 under single ascending dose and multiple ascending dose conditions.
Dr. Qunsheng Ji, CEO of Sirius Therapeutics, stated"The completion of the first subject's dosing marks the beginning of our global development of SRSD107, to evaluate its potential as a transformative anticoagulant drug that could achieve a dosing frequency of six months or longer while reducing the risk of bleeding. Additionally, another siRNA therapy developed by Sirius Therapeutics for treating dyslipidemia, SRSD101, has received IND approval from the China National Medical Products Administration and has entered clinical trials."
Sirius Therapeutics is an innovative biotechnology company dedicated to advancing human health and well-being. Focused on the development of next-generation nucleic acid therapies for cardiovascular diseases, the company aims to become a leader in revolutionizing the prevention and treatment of chronic conditions. Founded in 2021, it was incubated by an internationally renowned management team and globally recognized healthcare investment institutions. With an international strategic positioning, the company leverages talent and resources from both the U.S. and China, establishing a discovery hub for innovation in the U.S. and a global translational medicine center in China. Utilizing its proprietary core technology platform for small nucleic acid drug development, Sirius Therapeutics has built a robust pipeline of products with first-in-class or best-in-class potential and global competitive advantages. In October 2023, the company completed a $60 million Series B financing round, bringing its total funding to nearly $100 million.
Disclaimer:
The content of the article is for reference only and does not constitute investment advice. Investors who take actions based on this information bear their own risks. The article maintains a neutral stance regarding any statements or viewpoints, and does not provide any explicit or implicit guarantees concerning the accuracy, reliability, or completeness of the content. Readers are advised to use the information as a reference only and assume full responsibility for their actions. The various articles published by this official account aim to share information; if there is any infringement, please contact us, and we will delete the content.
Booths for the Class of 2024 are now available for booking!
(Sponsorship forms include but are not limited toSpeaking slots, exhibition booths, color pages in the conference proceedings, dinner sponsorship, promotional conference materials, etc.)
Scan to consult immediately!
Contact Number: 17521760400 (Same as WeChat)
Email: marketing@truesaw.com